| Literature DB >> 10199933 |
Y Chu1, H M Hu, H Winter, W J Wood, T Doran, D Lashley, J Bashey, J Schuster, J Wood, B A Lowe, J T Vetto, A D Weinberg, R Puri, J W Smith, W J Urba, B A Fox.
Abstract
Recently, it was recognized that an immune response develops along one of two major pathways. One leads to a destructive immune response (type 1), while the alternative leads to a nondestructive immune response (type 2). Our studies in animal models suggest that therapeutic vaccines induce a tumor-specific type 1 immune response while ineffective vaccines induce a type 2 response. These results have led us to examine the immune response in sentinel lymph nodes draining tumor vaccines of patients entered onto clinical trials for melanoma, breast and renal cell cancer.Entities:
Mesh:
Substances:
Year: 1999 PMID: 10199933 DOI: 10.1007/s002590050578
Source DB: PubMed Journal: Eur J Nucl Med ISSN: 0340-6997